This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Macular Degeneration  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic

Ziad F. Bashshur, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

Huang et al point out the problem with rises in IOP following an intravitreal injection of 2.5 mg of bevacizumab. We did not perform a paracentesis on any patient in our study¹ because all IOPs were less than 25 mm Hg within minutes after the injection. A perfused optic nerve and central retinal artery correlated well with an IOP of less than 25 mm Hg. For this reason, we no longer measure IOP after an injection and rely instead on the perfusion status of the optic nerve and central retinal artery. Applanation tonometry may introduce pathogens to the surface of the eye and increase the risk of endophthalmitis. We measure IOP in situations when it is not possible to see the retina (eg, vitreous hemorrhage). In cases of a possibly compromised retinal or optic nerve circulation, as in retinal vein occlusion, diabetic retinopathy, or . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

Necessity of Paracentesis Before or After Intravitreal Injection of Bevacizumab
Wei-Cheng Huang, Jane-Ming Lin, Chun-Chi Chiang, and Yi-Yu Tsai
Arch Ophthalmol. 2008;126(9):1314-1315.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Ziad F. Bashshur, Alexandre Schakal, Rola N. Hamam, Christelle P. El Haibi, Rola F. Jaafar, and Baha’ N. Noureddin
Arch Ophthalmol. 2007;125(10):1357-1361.
ABSTRACT | FULL TEXT